Cargando…

Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer

Recent clinical trials demonstrating the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the 'synthetic lethal' concept of targeted cancer therapeutics. A new study provides further preclinical validatio...

Descripción completa

Detalles Bibliográficos
Autor principal:	Wicha, Max S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790845/ https://www.ncbi.nlm.nih.gov/pubmed/19804613 http://dx.doi.org/10.1186/bcr2362

Ejemplares similares

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
por: Ratz, Leonie, et al.
Publicado: (2022)

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
por: Noll, Aurélia, et al.
Publicado: (2016)

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
por: Zhang, Baoyuan, et al.
Publicado: (2020)

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
por: Hu, Yunlong, et al.
Publicado: (2020)

MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
por: Srinivasan, Gayathri, et al.
Publicado: (2019)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting
por: Ronson, George E., et al.
Publicado: (2023)

Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells
por: García, Iris A., et al.
Publicado: (2020)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
por: Yang, Qianye, et al.
Publicado: (2021)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

Cancer stem cell heterogeneity in hereditary breast cancer
por: Wicha, Max S
Publicado: (2008)

The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells
por: Hromas, Robert, et al.
Publicado: (2017)

Genome-wide RNAi to identify genes that confer synthetic lethality with BRCA1
por: Petalcorin, MIR, et al.
Publicado: (2006)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

Mammary stem cell number as a determinate of breast cancer risk
por: Ginestier, Christophe, et al.
Publicado: (2007)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
por: Shields, Julie A., et al.
Publicado: (2022)

Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells
por: Tseng, Wei-Che, et al.
Publicado: (2021)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
por: Giovannini, Sara, et al.
Publicado: (2019)

miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells
por: Crippa, Elisabetta, et al.
Publicado: (2016)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
por: McAllister, Kimberly A, et al.
Publicado: (2002)

Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021)

Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)

Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer
por: Ozturk, Sait, et al.
Publicado: (2020)

The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition
por: Alqahtani, Shaherah, et al.
Publicado: (2019)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

Epigenetic based synthetic lethal strategies in human cancers
por: Gao, Aiai, et al.
Publicado: (2020)

Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
por: Han, Mingqi, et al.
Publicado: (2019)

Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52–ssDNA association
por: Li, Jian, et al.
Publicado: (2018)

Breast tumors: of mice and women
por: McDermott, Sean P, et al.
Publicado: (2010)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan
por: Jankowitz, Rachel C., et al.
Publicado: (2013)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells
por: Sajesh, Babu V., et al.
Publicado: (2015)

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
por: Lazo, Pedro A.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v9qeq76q5skncki032ihmnrroh